AUTHOR INDEX

(P = Proceedings)

AARONSON, D. *see* KAISER, H.
ABBINK, E.J., PICKKERS, P., VAN ROSENDAAL, A.J. & SMITS, P. Vascular effects of glibenclamide and glimepiride in type 2 diabetic patients, 780P
ABDELMAWLA, A.H., LANGLEY, R.W., SZABADI, E. & BRADSHAW, C.M. Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein, 345
ÅBERG-WISTEDT, A. *see* BRYNNE, N.
ADJEI, A.A. A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer, 265
AHERNE, G.W. *see* HAIN, R.D.W.
AHLSTRÖM, H., ALVERO, J., ALVERO, R., ESPOS, R., FAJUTRAO, L., HERRERA, J., KJELLMAN, B., KUBISTA, J., LEVISTE, C., MEYER, P., OLDÆUS, G., SIRICURURAT, A., VICHYANOND, P., WETTRELL, G., WONG, E., LAXMYR, L., NYBERG, L., OLSSON, H., WEIBULL, E. & ROSENBORG, J. Pharmacokinetics of bambuterol during oral administration to asthmatic children, 299
AITCHISON, K.J., MUNRO, J., WRIGHT, P., SMITH, S., MAKOFF, A.J., SACHSE, C., SHAM, P.C., MURRAY, R.M., COLLIER, D.A. & KERWIN, R.W. Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation, 388
ALEXANDER, S.PH. *see* PEIRCE, N.S.
ALLAN, L.M. *see* BROWN, N.
ALVERO, J. *see* AHLSTRÖM, H.
ALVERO, R. *see* AHLSTRÖM, H.
AMMON, S., HOFMANN, U., GRIESE, E.-U., GUGELER, N. & MIKUS, G. Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing, 317
APPEL-DINGEMANSE, S. *see* NEUMAYER, H.-H.
ARMSTRONG, N.C. & ERNST, E. The treatment of eczema with Chinese herbs: a systematic review of randomized clinical trials, 262
ASHTON, M. *see* SVENSSON, U.S.H.
AYNACIOGLU, A.S., BROCKMÖLLER, J., BAUER, S., SACHSE, C., GÜZELBEY, P., ÖNGEN, Z., NACAK, M. & ROOTS, I. Frequency of cytochrome P450 *CYP2C9* variants in a Turkish population and functional relevance for phenytoin, 409
AYNACIOGLU, A.S., CASCORBI, I., GÜNGÖR, K., ÖZKUR, M., BEKIR, N., ROOTS, I. & BROCKMÖLLER, J. Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu and Thr164Ile polymorphisms in the β_2-adrenergic receptor among Turks, 761

BACK, D.J. *see* EAGLING, V.A.
BACK, D.J. *see* JONES, K.
BACK, D.J. *see* KEWN, S.
BACK, D.J. *see* PROFIT, L.
BACK, D.J. *see* SALES, S.D.
BAIRD, R.N. *see* LEWIS, D.R.
BALDWIN, S.J., CLARKE, S.E. & CHENERY, R.J. Characterization of the cytochrome P450 enzymes in the *in vitro* metabolism of rosiglitazone, 424
BANJAR, W.M.A., GAZZAZ, J., LANGLEY, R.W., BRADSHAW, C.M. & SZABADI, E. Effects of high ambient temperature on parasympathetically-mediated cardiovascular reflexes in man, 889P
BARKER, K.F. Antibiotic resistance: a current perspective, 109
BARNDT, I. *see* NEUMAYER, H.-H.
BASSETTI, D. *see* GATTI, G.
BASSETTI, M. *see* GATTI, G.
BATEMAN, D.N. A Guide to Training in Clinical Pharmacology in Europe, 765
BATEMAN, D.N. Clinical pharmacology and therapeutics in a changing world, 1
BATHUM, L. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population, 395
BAUDOUIN, V. *see* DERVIEUX, T.
BAUER, S. *see* AYNACIOGLU, A.S.
BEARD, K. Side-effects of drugs: Annual 21, 641
BEARDSWORTH, S.A. *see* PURDIE, D.W.
BECKER, A. *see* DEBRIX, I.
BEEVERS, D.G. *see* GIBBS, C.R.
BEGG, E.J. *see* KRISTENSEN, J.H.
BEGG, E.J., DUFFULL, S.B., SAUNDERS, D.A., BUTTIMORE, R.C., ILETT, K.F., HACKETT, L.P., YAPP, P. & WILSON, D.A. Paroxetine in human milk, 142
BEIJNEN, J.H. *see* HUITEMA, A.D.R.
BEIJNEN, J.H. *see* KERBUSCH, T.
BEIJNEN, J.H. *see* MALINGRÉ, M.M.
BEKIR, N. *see* AYNACIOGLU, A.S.
BELLISSANT, E. & GIUDICELLI, J.-F. Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers, 801
BELTON, K.J. *see* ELAND, I.A.
BENET, L.Z. *see* MIZUMA, T.
BENNETT, P. Psychiatric disorders with a biochemical basis, 467
BENSON, H.A.E. *see* JIANG, R.
BERTILSSON, L. *see* BRYNNE, N.
BICKFORD, L., SHAKIB, S. & TAVERNER, D. The nasal airways response in normal subjects to oxymetazoline spray: randomized double-blind placebo-controlled trial, 53
BIOLLAZ, J. *see* BUCHWALDER-CSAJKA, C.
BIOLLAZ, J. *see* BUCLIN, T.
BIRK, K.L. *see* VAN HAARST, A.D.
BLECHERT, Å. *see* WAKELKAMP, M.
BLIN, O., JACQUET, A., CALLAMAND, S., JOUVE, E., HABIB, M., GAYRAUD, D., DURAND, A., BRUGUEROLLE, B. & PISANO, P. Pharmacokinetic–pharmacodynamic analysis of mnesic effects of lorazepam in healthy volunteers, 510
BLOCH, G. *see* WARY, C.
BLOOMER, J.C. *see* KENWORTHY, K.E.
BLUME, H.H. *see* GLEITER, C.H.
BOCHNER, F. *see* COLLER, J.K.
BONG, S.B. *see* MARING, J.G.
BÖTTIGER, Y., BRATTSTRÖM, C., TYDÉN, G, SÄWE, J. & GROTH, C.-G. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients, 445
BOYD, J.L. *see* WILKINSON, I.B.
BRADSHAW, C.M. *see* ABDELMAWLA, A.H.
BRADSHAW, C.M. *see* BANJAR, W.M.A.
BRADSHAW, C.M. *see* PHILLIPS, M.A.
BRAECKMAN, R. *see* KEMME, M.J.B.
BRAKENHOFF, J.P.G. *see* DOGTEROM, P.
BRATER, D.C. *see* GRUBB, N.G.
BRATTSTRÖM, C. *see* BÖTTIGER, Y.
BRENNAN, G. *see* SQUIRE, I.B.
BRESSEL, H.-U. *see* MICHEL, M.C.
BRETELER, M.M.B. *see* VAN DE VIJVER, D.A.M.C.
BRETT, S.E. *see* DAWES, M.
BRILLAULT-SALVAT, C. *see* WARY, C.
BROCKMÖLLER, J. *see* AYNACIOGLU, A.S.

© 1999 Blackwell Science Ltd

AUTHOR INDEX

(P = Proceedings)

AARONSON, D. *see* KAISER, H.
ABBINK, E.J., PICKKERS, P., VAN ROSENDAAL, A.J. & SMITS, P. Vascular effects of glibenclamide and glimepiride in type 2 diabetic patients, 780P
ABDELMAWLA, A.H., LANGLEY, R.W., SZABADI, E. & BRADSHAW, C.M. Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein, 345
ÅBERG-WISTEDT, A. *see* BRYNNE, N.
ADJEI, A.A. A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer, 265
AHERNE, G.W. *see* HAIN, R.D.W.
AHLSTRÖM, H., ALVERO, J., ALVERO, R., ESPOS, R., FAJUTRAO, L., HERRERA, J., KJELLMAN, B., KUBISTA, J., LEVISTE, C., MEYER, P., OLDÆUS, G., SIRICURURAT, A., VICHYANOND, P., WETTRELL, G., WONG, E., LAXMYR, L., NYBERG, L., OLSSON, H., WEIBULL, E. & ROSENBORG, J. Pharmacokinetics of bambuterol during oral administration to asthmatic children, 299
AITCHISON, K.J., MUNRO, J., WRIGHT, P., SMITH, S., MAKOFF, A.J., SACHSE, C., SHAM, P.C., MURRAY, R.M., COLLIER, D.A. & KERWIN, R.W. Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation, 388
ALEXANDER, S.PH. *see* PEIRCE, N.S.
ALLAN, L.M. *see* BROWN, N.
ALVERO, J. *see* AHLSTRÖM, H.
ALVERO, R. *see* AHLSTRÖM, H.
AMMON, S., HOFMANN, U., GRIESE, E.-U., GUGELER, N. & MIKUS, G. Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing, 317
APPEL-DINGEMANSE, S. *see* NEUMAYER, H.-H.
ARMSTRONG, N.C. & ERNST, E. The treatment of eczema with Chinese herbs: a systematic review of randomized clinical trials, 262
ASHTON, M. *see* SVENSSON, U.S.H.
AYNACIOGLU, A.S., BROCKMÖLLER, J., BAUER, S., SACHSE, C., GÜZELBEY, P., ÖNGEN, Z., NACAK, M. & ROOTS, I. Frequency of cytochrome P450 *CYP2C9* variants in a Turkish population and functional relevance for phenytoin, 409
AYNACIOGLU, A.S., CASCORBI, I., GÜNGÖR, K., ÖZKUR, M., BEKIR, N., ROOTS, I. & BROCKMÖLLER, J. Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu and Thr164Ile polymorphisms in the β_2-adrenergic receptor among Turks, 761

BACK, D.J. *see* EAGLING, V.A.
BACK, D.J. *see* JONES, K.
BACK, D.J. *see* KEWN, S.
BACK, D.J. *see* PROFIT, L.
BACK, D.J. *see* SALES, S.D.
BAIRD, R.N. *see* LEWIS, D.R.
BALDWIN, S.J., CLARKE, S.E. & CHENERY, R.J. Characterization of the cytochrome P450 enzymes in the *in vitro* metabolism of rosiglitazone, 424
BANJAR, W.M.A., GAZZAZ, J., LANGLEY, R.W., BRADSHAW, C.M. & SZABADI, E. Effects of high ambient temperature on parasympathetically-mediated cardiovascular reflexes in man, 889P
BARKER, K.F. Antibiotic resistance: a current perspective, 109
BARNDT, I. *see* NEUMAYER, H.-H.
BASSETTI, D. *see* GATTI, G.
BASSETTI, M. *see* GATTI, G.
BATEMAN, D.N. A Guide to Training in Clinical Pharmacology in Europe, 765
BATEMAN, D.N. Clinical pharmacology and therapeutics in a changing world, 1
BATHUM, L. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population, 395
BAUDOUIN, V. *see* DERVIEUX, T.
BAUER, S. *see* AYNACIOGLU, A.S.
BEARD, K. Side-effects of drugs: Annual 21, 641
BEARDSWORTH, S.A. *see* PURDIE, D.W.
BECKER, A. *see* DEBRIX, I.
BEEVERS, D.G. *see* GIBBS, C.R.
BEGG, E.J. *see* KRISTENSEN, J.H.
BEGG, E.J., DUFFULL, S.B., SAUNDERS, D.A., BUTTIMORE, R.C., ILETT, K.F., HACKETT, L.P., YAPP, P. & WILSON, D.A. Paroxetine in human milk, 142
BEIJNEN, J.H. *see* HUITEMA, A.D.R.
BEIJNEN, J.H. *see* KERBUSCH, T.
BEIJNEN, J.H. *see* MALINGRÉ, M.M.
BEKIR, N. *see* AYNACIOGLU, A.S.
BELLISSANT, E. & GIUDICELLI, J.-F. Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers, 801
BELTON, K.J. *see* ELAND, I.A.
BENET, L.Z. *see* MIZUMA, T.
BENNETT, P. Psychiatric disorders with a biochemical basis, 467
BENSON, H.A.E. *see* JIANG, R.
BERTILSSON, L. *see* BRYNNE, N.
BICKFORD, L., SHAKIB, S. & TAVERNER, D. The nasal airways response in normal subjects to oxymetazoline spray: randomized double-blind placebo-controlled trial, 53
BIOLLAZ, J. *see* BUCHWALDER-CSAJKA, C.
BIOLLAZ, J. *see* BUCLIN, T.
BIRK, K.L. *see* VAN HAARST, A.D.
BLECHERT, Å. *see* WAKELKAMP, M.
BLIN, O., JACQUET, A., CALLAMAND, S., JOUVE, E., HABIB, M., GAYRAUD, D., DURAND, A., BRUGUEROLLE, B. & PISANO, P. Pharmacokinetic–pharmacodynamic analysis of mnesic effects of lorazepam in healthy volunteers, 510
BLOCH, G. *see* WARY, C.
BLOOMER, J.C. *see* KENWORTHY, K.E.
BLUME, H.H. *see* GLEITER, C.H.
BOCHNER, F. *see* COLLER, J.K.
BONG, S.B. *see* MARING, J.G.
BÖTTIGER, Y., BRATTSTRÖM, C., TYDÉN, G, SÄWE, J. & GROTH, C.-G. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients, 445
BOYD, J.L. *see* WILKINSON, I.B.
BRADSHAW, C.M. *see* ABDELMAWLA, A.H.
BRADSHAW, C.M. *see* BANJAR, W.M.A.
BRADSHAW, C.M. *see* PHILLIPS, M.A.
BRAECKMAN, R. *see* KEMME, M.J.B.
BRAKENHOFF, J.P.G. *see* DOGTEROM, P.
BRATER, D.C. *see* GRUBB, N.G.
BRATTSTRÖM, C. *see* BÖTTIGER, Y.
BRENNAN, G. *see* SQUIRE, I.B.
BRESSEL, H.-U. *see* MICHEL, M.C.
BRETELER, M.M.B. *see* VAN DE VIJVER, D.A.M.C.
BRETT, S.E. *see* DAWES, M.
BRILLAULT-SALVAT, C. *see* WARY, C.
BROCKMÖLLER, J. *see* AYNACIOGLU, A.S.

© 1999 Blackwell Science Ltd

BRODDE, O.-E. *see* SCHMUCK, S.
BROEDERS, M.E.A.C., HEIJDRA, Y.F., FOLGERING, H. TH.M., SMITS, P. & KRAMERS, C. Effects of verapamil on the nocturnal O_2-saturation in patients with chronic obstructive pulmonary disease, 772P
BROHIER, S. *see* ROSENZWEIG, P.
BROLY, F. *see* DERVIEUX, T.
BROOKS, S.T. *see* LEWIS, D.R.
BRØSEN, K. *see* DAMKIER, P.
BRØSEN, K. *see* LARSEN, J.T.
BROUWERS, J.R.B.J. *see* FIJN, R.
BROWN, N., MAY, J.A., WILCOX, R.G., ALLAN, L.M., WILSON, A.M., KIFF, P.S. & HEPTINSTALL, S. Comparison of antiplatelet activity of microencapsulated aspirin 162.5 mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis, 57
BRUGUEROLLE, B. *see* BLIN, O.
BRUNNER, H.R. *see* BUCHWALDER-CSAJKA, C.
BRUNNER, H.R. *see* BUCLIN, T.
BRYNNE, N., FORSLUND, C., HALLÉN, B., GUSTAFSSON, L.L. & BERTILSSON, L. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity, 564
BRYNNE, N., SVANSTRÖM, C., ÅBERG-WISTEDT, A., HALLÉN, B. & BERTILSSON, L. Fluoxetine inhibits the metabolism of tolterodine—pharmacokinetic implications and proposed clinical relevance, 553
BUCHWALDER-CSAJKA, C. *see* BUCLIN, T.
BUCHWALDER-CSAJKA, C., BUCLIN, T., BRUNNER, H.R. & BIOLLAZ, J. Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system, 594
BUCLIN, T. *see* BUCHWALDER-CSAJKA, C.
BUCLIN, T., BUCHWALDER-CSAJKA, C., BRUNNER, H.R. & BIOLLAZ, J. Evaluation of noninvasive blood pressure recording by photoplethysmography in clinical studies using angiotensin challenges, 586
BUDDE, K. *see* NEUMAYER, H.-H.
BURGGRAAF, J. *see* KEMME, M.J.B.
BURKHARDT, K. *see* NEUMAYER, H.-H.
BUTTER, J.J. *see* DERKS, M.G.M.
BUTTER, J.J. *see* NAGY, J.
BUTTER, J.J. *see* SCHIPPER, H.G.
BUTTIMORE, R.C. *see* BEGG, E.J.
BUU SAO, A. *see* RAGUENEAU, I.
CALLAMAND, S. *see* BLIN, O.
CALVERT, R. *see* ROSTAMI-HODJEGAN, A.
CAMERON, D.W. *see* GALLICANO, K.D.
CAPUTI, A. *see* NALDI, L.
CARLIER, P.G. *see* WARY, C.
CASAROTTO, D. *see* PADRINI, R.
CASCORBI, I. *see* AYNACIOGLU, A.S.
CASTELLI, F. *see* VILLANI, P.
CASTELLSAGUE, J. *see* GARCÍA RODRIGUEZ, L.A.
CEVALLOS, W. *see* DANJOU, P.
CHAN, A.T.C. *see* CHANG, S.
CHAN, K. *see* CHEN, A.G.
CHAN, L.S.Y. *see* CHANG, S.
CHANG, S., LI, R.C., CHAN, L.S.Y., WONG, S.Y., ZHU, M., CHAN, A.T.C. & RAYMOND, K. Netilmicin pharmacokinetics in Hong Kong Chinese cancer patients, 33
CHARLES, B. *see* PREECHAGOON, Y.
CHARLETT, A., DOBBS, S.M., DOBBS, R.J., PETERSON, D.W. & WELLER, C. Could antibodies to *Heliobacter pylori* urease explain the facets of parkinsonism quantified in subjects who have and have not passed the diagnostic threshold? 888P
CHEN, A.G., ROWE, P.H., WING, Y.K., CHIU, H. & CHAN, K. Plasma levels and clinical response to imipramine in Chinese depressed patients, 886P
CHEN, H. *see* JIANG, J.
CHENERY, R.J. *see* BALDWIN, S.J.
CHILDS, A. *see* KEMME, M.J.B.
CHIU, H. *see* CHEN, A.G.
CHONG SHU, C. *see* XIAO DONG, S.
CHOONARA, I. *see* IMPICCIATORE, P.
CHOWIENCZYK, P.J. *see* DAWES, M.
CHOWIENCZYK, P.J. *see* RAJMAN, I.
CHUNG, M., VASHI, V., PUENTE, J., SWEENEY, M. & MEREDITH, P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation, 678
CLARKE, S.E. *see* BALDWIN, S.J.
CLARKE, S.E. *see* KENWORTHY, K.E.
CLAY, M.E. *see* MITCHELL, D.Y.
COCCI, A. *see* NALDI, L.
COCKCROFT, J.R. *see* McENIERY, C.M.
COCKCROFT, J.R. *see* WILKINSON, I.B.
COHEN, A.F. *see* KEMME, M.J.B.
COHEN, A.F. *see* VAN HAARST, A.D.
COLLER, J.K., SOMOGYI, A.A. & BOCHNER, F. Comparison of (S)-mephenytoin and proguanil oxidation *in vitro*: contribution of several CYP isoforms, 158
COLLIER, D.A. *see* AITCHISON, K.J.
COLLIER, J. Paediatric prescribing: using unlicensed drugs and medicines outside their licensed indications, 5
COLLIN, M. & MUCKLOW, J.C. Drug interactions, renal impairment and hypoglycaemia in a patient with Type II diabetes, 134
COLLINS, D.M. *see* JIANG, R.
COLLINS, J.M. *see* LI, A.P.
CONFORTI, A. *see* NALDI, L.
COUTIE, W.J. *see* LEE, A.F.C.
CZEIZEL, A.E. *see* SØRENSEN, H.T.

D'URSO, S. *see* XIAO DONG, S.
DALVI, S.S. *see* GOGTAY, N.J.
DAMKIER, P., HANSEN, L.L. & BRØSEN, K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine, 829
DANJOU, P., PATY, I., FRUNCILLO, R., WORTHINGTON, P., UNRUH, M., CEVALLOS, W. & MARTIN, P. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening, 367
DARGIE, H.J. *see* SQUIRE, I.B.
DAWES, M., BRETT, S.E., CHOWIENCZYK, P.J., MANT, T.G.K. & RITTER, J.M. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension, 460
DAWSON, A.H. & WHYTE, I.M. Therapeutic drug monitoring in drug overdose, 278
DAY, A. *see* LEWIS, D.R.
DE BOER, A. *see* VAN DE VIJVER, D.A.M.C.
DE CRAEN, A.J.M., MOERMAN, D.E., HEISTERKAMP, S.H., TYTGAT, G.N.J., TIJSSEN, J.G.P. & KLEIJNEN, J. Placebo effect in the treatment of duodenal ulcer, 853
DE GRAEFF, P.A. *see* GANSEVOORT, R.T.
DE GRAUW, H.A.G. *see* SCHIFFERS, S.L.H.
DE HOON, J.N.J.M., PICKKERS, P., SMITS, P., STRUIJKER-BOUDIER, H.A.J. & VAN BORTEL, L.M.A.B. Calcitonin gene-related peptide induced vasodilation in man: the contribution of potassium channels, 774P
DE JONG, P.E. *see* GANSEVOORT, R.T.
DE JONG-VAN DEN BERG, L.T.W. *see* FIJN, R.
DE PASCALIS, C.R. *see* GATTI, G.
DE PUY, M.E. *see* VAN HAARST, A.D.
DE SMET, M. *see* VAN HAARST, A.D.
DE STOPPELAAR, F. *see* STOLK, L.
DE VREEDE, P. *see* SAMSON, M.M.
DE VRIES, E.G.E. *see* MARING, J.G.

DEBRIX, I., FLAHAULT, A., BECKER, A., SCHWARTZ, L., KANFER, A. & MILLERON, B. Impact of guidelines implemented in a Paris university hospital: application to the use of antiemetics by cancer patients, 616
DEGRAEUWE, P.L.J. *see* STOLK, L.
DEICHSEL, G. *see* THEIS, J.G.W.
DEKENS, K.G. *see* MARING, J.G.
DERKS, M.G.M., BUTTER, J.J., DUBOIS, E.F.L. & VAN BOXTEL, C.J. Differential kinetics of formoterol enantiomers and the effects on plasma potassium and pulmonary function, 772P
DERKS, M.G.M., KOOPMANS, R.P., OOSTERHOFF, E. & VAN BOXTEL, C.J. Prevention by theophylline of β_2-adrenoceptor downregulation in healthy subjects, 782P
DERVIEUX, T., MÉDARD, Y., BAUDOUIN, V., MAISIN, A., ZHANG, D., BROLY, F., LOIRAT, C. & JACQZ-AIGRAIN, E. Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine, 793
DEURINGER, F.U. *see* MUECK, A.O.
DI BIAGIO, A. *see* GATTI, G.
DI GIROLAMO, A. *see* O'NEIL, W.M.
DOBBS, R.J. *see* CHARLETT, A.
DOBBS, S.M. *see* CHARLETT, A.
DOCKHORN, R. *see* KAISER, H.
DOGTEROM, P., VAN MARLE, S.P., BRAKENHOFF, J.P.G., WEMER, J., UNGETHÜM, W., LADSTETTER, B. & JONKMAN, J.H.G. Pharmacokinetics and metabolism of [^{14}C]-EMD 61 753 (asimadoline), a new κ-opioid receptor agonist, in healthy male volunteers, 778P
DONNELLY, R. *see* KING, P.
DONOVAN, T. *see* PREECHAGOON, Y.
DUAN, S.X. *see* VON MOLTKE, L.L.
DUBOIS, E.F.L. *see* DERKS, M.G.M.
DUCHIN, K.L. *see* MALINGRÉ, M.M.
DUFFULL, S.B. *see* BEGG, E.J.
DUIJKERS, I.J.M., KLIPPING, C., WILLEMSEN, W.N.P., KRONE, D., SCHNEIDER, E. NIEBCH, G., ROMEIS, P. & HERMANN, R. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotropin-releasing hormone antagonist cetrorelix in healthy female, 774P
DUNN, N.R., FREEMANTLE, S.N. & MANN, R.D. Cohort study on calcium channel blockers, other cardiovascular agents, and the prevalence of depression, 230
DUQUE, A. *see* GARCÍA RODRÍGUEZ, L.A.
DURAND, A. *see* BLIN, O.
DYNAN, K.B. *see* MCGLEENON, B.M.

EACHO, P.I. *see* RAJMAN, I.
EAGLING, V.A., PROFIT, L. & BACK, D.J. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components, 543
EDSBÄCKER, S. *see* KAISER, H.
EDWARDS, I.R. Spontaneous reporting — of what? Clinical concerns about drugs, 138
ELAND, I.A., BELTON, K.J., VAN GROOTHEEST, A.C., MEINERS, A.P., RAWLINS, M.D. & STRICKER, B.H.CH. Attitudinal survey of voluntary reporting of adverse drug reactions, 623
ELZE, M. *see* GLEITER, C.H.
ERIKSSON, M. *see* WAKELKAMP, M.
ERNST, E. *see* ARMSTRONG, N.C.
ERVINE, C.M. *see* HUGHES, A.M.
ESPOS, R. *see* AHLSTRÖM, H.
EVANS, B.K. *see* GREEN, J.T.

FAIRWEATHER, D.B. *see* HINDMARCH, I.
FAJUTRAO, L. *see* AHLSTRÖM, H.
FAN, F. *see* JIANG, J.
FATTORE, C. *see* XIAO DONG, S.
FEENSTRA, J., MOSTERD, A., GROBBEE, D.E. & STRICKER, B.H.Ch. Non-steroidal anti-inflammatory drugs and systolic cardiac function, 766P
FERRARI, M. *see* PADRINI, R.
FERRO, C.J. *see* NEWBY, D.E.
FEYERABEND, C. *see* GREEN, J.T.
FIEGER-BÜSCHGES, H. *see* GLEITER, C.H.
FIJN, R., BROUWERS, J.R.B.J., KNAAP, R.J. & DE JONG-VAN DEN BERG, L.T.W. Drug and Therapeutics (D & T) committees in Dutch hospitals: a nation-wide survey of structure, activities, and drug selection procedures, 239
FISHER, A.L. *see* VAN HAARST, A.D.
FISHER, I., ROBINSON, P. & RITTER, J.M. Platelet glycoprotein IIb/IIIa blockade with tirofiban: effect on aggregation caused by P256, an antibody to human IIb/IIIa receptors, 197
FLAHAULT, A. *see* DEBRIX, I.
FLOR, B. *see* VILA, J.MA.
FOLGERING, H. TH.M. *see* BROEDERS, M.E.A.C.
FORD, G.A. *see* MCCABE, N.
FORETTE, B. *see* HORNYCH, A.
FORSLUND, C. *see* BRYNNE, N.
FOSTER, B.C. *see* GALLICANO, K.D.
FOTTELER, B. *see* JORGA, K.
FREEMANTLE, S.N. *see* DUNN, N.R.
FREUDENTHALER, S. *see* GLEITER, C.H.
FREUDENTHALER, S.M., SCHENCK, T., LUCHT, I. & GLEITER, C.H. Fenoterol stimulates human erythropoietin production via activation of the renin angiotensin system, 631
FREYSZ, M. *see* LENFANT, F.
FRITSCHE, L. *see* NEUMAYER, H.-H.
FRUNCILLO, R. *see* DANJOU, P.
FUJITAKA, M. *see* KATO, Y.
FUNCK-BRENTANO, C. *see* RAGUENEAU, I.

GALLICANO, K.D., SAHAI, J., SHUKLA, V.K., SEGUIN, I., PAKUTS, A., KWOK, D., FOSTER, B.C. & CAMERON, D.W. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients, 168
GANSEVOORT, R.T., MEIJER, R.P., MEIJER, R.P., VULINK, A.J.E., SLUITER, W.J., DE GRAEFF, P.A., DE JONG, P.E. & ZEEUW, D. A meta-analysis of the antihypertensive efficacy of angiotensin II antagonists, 777P
GARCÍA RODRÍGUEZ, L.A., DUQUE, A., CASTELLSAGUE, J., PÉREZ-GUTTHANN, S. & STRICKER, B.H.CH. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs, 847
GASSER, R. *see* JORGA, K.
GATTI, G. *see* XIAO DONG, S.
GATTI, G., DI BIAGIO, A., DE PASCALIS, C.R., GUERRA, M., BASSETTI, M. & BASSETTI, D. Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome, 704
GAYRAUD, D. *see* BLIN, O.
GAZZAZ, J. *see* BANJAR, W.M.A.
GERTZ, B.J. *see* NEWBY, D.E.
GHIOTTO, E. *see* NALDI, L.
GIBBS, C.R., LIP, G.Y.H. & BEEVERS, D.G. Angiodema due to ACE inhibitors: increased risk in patients of African origin, 861
GIRAULT, F. *see* HORNYCH, A.
GIUDICELLI, J.-F. *see* BELLISSANT, E.
GIUGNO, I. *see* MALAGUARNERA, M.
GJELLAN, K. *see* WAKELKAMP, M.
GLEITER, C.H. *see* FREUDENTHALER, S.M.
GLEITER, C.H., SCHREEB, K.H., FREUDENTHALER, S., THOMAS, M., ELZE, M., FIEGER-BÜSCHGES, H., POTTHAST, H., SCHNEIDER, E., SCHUG, B.S., BLUME, H.H. & HERMANN, R. Lack of interaction

between thioctic acid, glibenclamide and acarbose, 819
GOEPEL, M. *see* MICHEL, M.C.
GOGTAY, N.J., KSHIRSAGAR, N.A. & DALVI, S.S. Therapeutic drug monitoring in a developing country: an overview, 649
GOLDBERG, M.R. *see* VAN HAARST, A.D.
GRAFFNER, C. *see* WAKELKAMP, M.
GRANDA, B.W. *see* VON MOLTKE, L.L.
GRASSI, J.M. *see* VON MOLTKE, L.L.
GREEN, J.T., EVANS, B.K., RHODES, J., THOMAS, G.A.O., RANSHAW, C., FEYERABEND, C. & RUSSELL, M.A.H. An oral formulation of nicotine for release and absorption in the colon: its development and pharmacokinetics, 485
GREENBLATT, D.J. *see* VON MOLTKE, L.L.
GREGORY, A. *see* MANAP, R.A.
GRIESE, E.-U. *see* AMMON, S.
GROBBEE, D.E. *see* FEENSTRA, J.
GROEN, H., VAN MARLE, S.P., VOLKERS, C.P., NEMANSKY, M., WEMER, J., ZECH, K., MASCHER, H. & JONKMAN, J.H.G. A study to investigate the pharmacokinetics and metabolism of budipine after administration of a single oral dose of [^{14}C]-B757-01 to six healthy volunteers, 771P
GROENEWOLD, O.G. *see* MARING, J.G.
GROGNET, J.-M. *see* WARY, C.
GROND, S., MEUSER, T., URAGG, H., STAHLBERG, H.J. & LEHMANN, K.A. Serum concentrations of tramadol enantiomers during patient-controlled analgesia, 254
GROSSMANN, M., JAMIESON, M.J. & KIRCH, W. Histamine response and local cooling in the human skin: involvement of H_1-and H_2-receptors, 216
GROTH, C.-G. *see* BÖTTIGER, Y.
GRUBB, N.G., RUDY, D.W., BRATER, D.C. & HALL, S.D. Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination, 494
GUERRA, M. *see* GATTI, G.
GUGELER, N. *see* AMMON, S.
GÜNGÖR, K. *see* AYNACIOGLU, A.S.
GUPTA, S.K., SHAH, J.C. & HWANG, S.W. Pharmacokinetic and pharmacodynamic characterization of OROS® and immediate-release amitriptyline, 71
GUSLANDI, M. Nicotine treatment for ulcerative colitis, 481
GUSTAFSSON, L.L. *see* BRYNNE, N.
GÜZELBEY, P. *see* AYNACIOGLU, A.S.

HABIB, M. *see* BLIN, O.
HACKETT, L.P. *see* BEGG, E.J.
HACKETT, L.P. *see* KRISTENSEN, J.H.
HAIN, R.D.W., HARDCASTLE, A., PINKERTON, C.R. & AHERNE, G.W. Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children, 37
HALL, K.S. *see* WALKER, D.K.
HALL, S.D. *see* GRUBB, N.G.
HALLÉN, B. *see* BRYNNE, N.
HANSEN, L.L. *see* DAMKIER, P.
HANSEN, L.L. *see* LARSEN, J.T.
HARDCASTLE, A. *see* HAIN, R.D.W.
HARKER, A. *see* JIANG, J.
HARMATZ, J.S. *see* VON MOLTKE, L.L.
HART, C.A. *see* SALES, S.D.
HARTMAN, N.R. *see* LI, A.P.
HAUSER, I.A. *see* NEUMAYER, H.-H.
HAY, A.W.M. *see* ROSTAMI-HODJEGAN, A.
HE, G.-W. & YANG, C.-Q. Comparison of the vasorelaxant effect of nitroprusside and nitroglycerin in the human radial artery *in vitro*, 99
HE, G.-W. & YANG, C.-Q. Inhibition of vasoconstriction by the thromboxane A_2 antagonist GR32191B in the human radial artery, 207
HEIJDRA, Y.F. *see* BROEDERS, M.E.A.C.
HEISE, M.A. *see* MITCHELL, D.Y.
HEISTERKAMP, S.H. *see* DE CRAEN, A.J.M.
HEIZMANN, P. *see* JORGA, K.
HENDERSON, C.J. *see* KITTERINGHAM, N.R.
HEPTINSTALL, S. *see* BROWN, N.
HERMANN, R. *see* DUIJKERS, I.J.M.
HERMANN, R. *see* GLEITER, C.H.
HERRERA, J. *see* AHLSTRÖM, H.
HINDMARCH, I., SHAMSI, Z., STANLEY, N. & FAIRWEATHER, D.B. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function, 200
HIRANO, T. *see* HORIGOME, A.
HOFMANN, U. *see* AMMON, S.
HOGGARD, P.G. *see* JONES, K.
HOGGARD, P.G. *see* KEWN, S.
HOGGARD, P.G. *see* SALES, S.D.
HOLFORD, N.H.G. Target concentration intervention: beyond Y2K, 9
HOOD, S. Changes in systolic time intervals – a noninvasive marker for the haemodynamic effects of sumatriptan, 331
HORIGOME, A., HIRANO, T., OKA, K., TAKEUCHI, H., SAKURAI, E., KOZAKI, K., MATSUNO, N., NAGAO, T. & KOZAKI, M. Lymphocyte-sensitivity to glucocorticoid correlates with the sensitivity to cyclosporin A and tacrolimus in chronic renal failure patients, 573
HORNYCH, A., GIRAULT, F., ORAVEC, S., FORETTE, B. & HORROBIN, D.F. Effect of gamma-linolenic acid on plasma and membrane lipids and renal prostaglandins in old subjects, 869
HORROBIN, D.F. *see* HORNYCH, A.
HOUSTON, J.B. *see* KENWORTHY, K.E.
HOVESTADT, A. *see* SAMSON, M.M.
HU, P. *see* JIANG, J.
HUGHES, A.M. 'Wind-up' model for the determination of the analgesic potential of NMDA receptor modulators in healthy volunteers, 878P
HUGHES, A.M., LYNCH, P., RHODES, J., ERVINE, C.M. & YATES, R.A. Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers, 323
HUITEMA, A.D.R. *see* KERBUSCH, T.
HUITEMA, A.D.R., KERBUSCH, T., TIBBEN, M.M., RODENHUIS, S. & BEIJNEN, J.H. Bioactivation of cyclophosphamide is strongly reduced by thiotepa *in vitro* and in cancer patients, 770P
HWANG, S.W. *see* GUPTA, S.K.

IKEDA, Y. *see* UMEMURA, K.
ILETT, K.F. *see* BEGG, E.J.
ILETT, K.F. *see* KRISTENSEN, J.H.
IMPICCIATORE, P. & CHOONARA, I. Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use, 15

JACKSON, C.M. *see* LIPWORTH, B.J.
JACQUET, A. *see* BLIN, O.
JACQZ-AIGRAIN, E. *see* DERVIEUX, T.
JAILLON, P. *see* RAGUENEAU, I.
JAKUBETZ, J. *see* SCHMUCK, S.
JAMIESON, M.J. *see* GROSSMANN, M.
JANSEN, P.A.F. *see* SAMSON, M.M.
JANSSON, B. *see* SANDSTRÖM, R.
JEAN, C. *see* NEUMAYER, H.-H.
JIANG, J., HU, P., XIE, H., CHEN, H., FAN, F., HARKER, A. & JOHNSON, M.A. The pharmacokinetics of lamivudine in healthy Chinese subjects, 250
JIANG, R., ROBERTS, M.S., COLLINS, D.M. & BENSON, H.A.E. Absorption of sunscreens across human skin: an evaluation of commercial products for children and adults, 635

JOHNSON, M.A. *see* JIANG, J.
JOHNSTON, G.D. *see* NUGENT, A.G.
JOHNSTON, S.M. *see* WILKINSON, I.B.
JONES, A.W. *see* KECHAGIAS, S.
JONES, K., HOGGARD, P.G. & BACK, D.J. Intracellular concentrations of the HIV protease inhibitors indinavir, ritonavir and saquinavir *in vitro*, 880P
JONKMAN, J.H.G. *see* DOGTEROM, P.
JONKMAN, J.H.G. *see* GROEN, H.
JÖNSSON, K.-Å. *see* KECHAGIAS, S.
JORGA, K., FOTTELER, B., HEIZMANN, P. & GASSER, R. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase, 513
JORGA, K.M. & NICHOLL, D.J. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients on levodopa/cardidopa (Sinemet®), 449
JOUVE, E. *see* BLIN, O.
JUNG, R.T. *see* LIM, P.O.

KAGER, P.A. *see* NAGY, J.
KAGER, P.A. *see* SCHIPPER, H.G.
KAISER, H., AARONSON, D., DOCKHORN, R., EDSBÄCKER, S., KORENBLAT, P. & KÄLLÉN, A. Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler®, 309
KÄLLÉN, A. *see* KAISER, H.
KANFER, A. *see* DEBRIX, I.
KARIM, A. *see* KEMME, M.J.B.
KATO, Y., MURAKI, K., FUJITAKA, M., SAKURA, N. & UEDA, K. Plasma concentrations of disodium cromoglycate after various inhalation methods in healthy subjects, 154
KECHAGIAS, S., JÖNSSON, K.-Å. & JONES, A.W. Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride, 728
KEIZER, H.J. *see* KERBUSCH, T.
KELM, G.R. *see* MANAP, R.A.
KEMME, M.J.B., BURGGRAAF, J., SCHOEMAKER, R.C., KARIM, A., PAULSON, S., CHILDS A., BRAECKMAN, R. & COHEN, A.F. The influence of reduced liver blood flow on the pharmacokinetics of recombinant tissue factor pathway inhibitor, 769P
KENDLE, K. *see* STEWART, D.
KENWORTHY, K.E., BLOOMER, J.C., CLARKE, S.E. & HOUSTON, J.B. CYP3A4 drug interactions: correlation of 10 *in vitro* probe substrates, 716
KERBUSCH, T. *see* HUITEMA, A.D.R.
KERBUSCH, T., HUITEMA, A.D.R., SCHELLENS, J.H.M., OUWERKERK, J., KEIZER, H.J. & BEIJNEN, J.H. NONMEM modelling of autoinducation and pharmacokinetics of ifosfamide in soft tissue sarcoma (STS), 780P
KERWIN, R.W. *see* AITCHISON, K.J.
KEWN, S., HOGGARD, P.G., SALES, S.D. & BACK, D.J. Intracellular activation of lamivudine (3TC) and determination of 2′-deoxycytidine-5′-triphosphate (dCTP) in the presence and absence of various drugs in HepG2 cells, 883P
KIELY, D.G. *see* LEE, A.F.C.
KIFF, P.S. *see* BROWN, N.
KIM, R.B. *see* XIE, H.G.
KING, P., PEACOCK, I. & DONNELLY, R. The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes, 643
KIRCH, W. *see* GROSSMANN, M.
KITTERINGHAM, N.R., POWELL, H., HENDERSON, C.J., WOLF, C.R. & PARK, B.K. Protection against paracetamol hepatotoxicity in glutathione S-transferase Pi knockout mice does not involve altered covalent binding, 887P
KIVISTÖ, K.T. *see* LAPATTO-REINILUOTO, O.
KJELLMAN, B. *see* AHLSTRÖM, H.
KLEIJNEN, J. *see* DE CRAEN, A.J.M.
KLIEM, V. *see* NEUMAYER, H.-H.
KLIPPING, C. *see* DUIJKERS, I.J.M.
KLOTZ, U. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline, 438
KLOTZ, U. *see* SCHWAB, M.
KNAAP, R.J. *see* FIJN, R.
KNUTSON, L. *see* SANDSTRÖM, R.
KNUTSON, T.W. *see* SANDSTRÖM, R.
KOBAYASHI, T. *see* UMEMURA, K.
KOLKMAN, J.J. *see* SCHUURMANS, A.
KONDO, K. *see* UMEMURA, K.
KOOPMANS, R.P. *see* DERKS, M.G.M.
KOOPMANS, R.P. *see* NAGY, J.
KOOPMANS, R.P. *see* SCHIPPER, H.G.
KORENBLAT, P. *see* KAISER, H.
KORN, A. *see* NEUMAYER, H.-H.
KOZAKI, K. *see* HORIGOME, A.
KOZAKI, M. *see* HORIGOME, A.
KRAMERS, C. *see* BROEDERS, M.E.A.C.
KRISTENSEN, J.H., ILETT, K.F., HACKETT, L.P., YAPP, P., PAECH, M. & BEGG, E.J. Distribution and excretion of fluoxetine and norfluoxetine in human milk, 521
KRIVANEK, P. *see* TURNHEIM, K.
KRONE, D. *see* DUIJKERS, I.J.M.
KRSKA, J. *see* STEWART, D.
KSHIRSAGAR, N.A. *see* GOGTAY, N.J.
KUBISTA, J. *see* AHLSTRÖM, H.
KWOK, D. *see* GALLICANO, K.D.

LADSTETTER, B. *see* DOGTEROM, P.
LAHET, J.J. *see* LENFANT, F.
LAMBROU, G. *see* RONGEN, G.A.
LAMONT, P.M. *see* LEWIS, D.R.
LANGLEY, R.W. *see* ABDELMAWLA, A.H.
LANGLEY, R.W. *see* BANJAR, W.M.A.
LANGLEY, R.W. *see* PHILLIPS, M.A.
LAPATTO-REINILUOTO, O., KIVISTÖ, K.T. & NEUVONEN, P.J. Effect of activated charcoal alone or given after gastric lavage in reducing the absorption of diazepam, ibuprofen and citalopram, 148
LARSEN, H. *see* SØRENSEN, H.T.
LARSEN, J.T., HANSEN, L.L. & BROSEN, K. Tacrine is not an ideal probe drug for measuring CYP1A2 activity *in vivo*, 663
LAXMYR, L. *see* AHLSTRÖM, H.
LEANING, M. *see* VADHER, B.
LECLERC, J.H. *see* WARY, C.
LEE, A.F.C., KIELY, D.G., COUTIE, W.J. & STRUTHERS, A.D. The effect of nitric oxide inhibition on the renin response to frusemide, in man, 355
LEENEN, F.H.H. *see* TAN, K.W.
LEHMANN, K.A. *see* GROND, S.
LEMON, M.J.C. *see* LEWIS, D.R.
LENFANT, F., LAHET, J.J., VOLOT, F., SCHAFER, I., FREYSZ, M. & ROCHETTE, L. Effects of bupivacaine on human erythrocytes submitted to stress and evidence for an interaction between bupivacaine and flumazenil, 826
LENNARD, M.S. *see* MANAP, R.A.
LENNARD, M.S. *see* TOOLEY, A.
LENNERNÄS, H. *see* SANDSTRÖM, R.
LEONE, R. *see* NALDI, L.
LEROY-WILLIG, A. *see* WARY, C.
LEVISTE, C. *see* AHLSTRÖM, H.
LEWIS, D.R., LEMON, M.J.C., TABERNER, P.V., DAY, A., SHIH, M.-F., BROOKS, S.T., BAIRD, R.N., LAMONT, P.M. & SMITH, F.C.T. Gender-dependence of the association of vein graft re-stenosis with dyslipidaemia and lipoprotein lipase activity, 874P
LI, A.P., HARTMAN, N.R., LU, C., COLLINS, J.M. & STRONG, J.M. Effects of cytochrome P450 inducers on 17α-ethinyloestradiol (EE_2) conjugation by primary human hepatocytes, 733
LI, R.C. *see* CHANG, S.
LIM, P.O., JUNG, R.T. & MACDONALD, T.M. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study, 756
LIN, E.T. *see* MIZUMA, T.
LINS, R. *see* O'GRADY, P.
LIP, G.Y.H. *see* GIBBS, C.R.

© 1999 Blackwell Science Ltd

LIPPERT, T.H. *see* MUECK, A.O.
LIPWORTH, B.J. & JACKSON, C.M. Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate, 866
LIPWORTH, B.J. *see* WILSON, A.M.
LISON, A.-E. *see* NEUMAYER, H.-H.
LLUCH, P. *see* VILA, J.MA.
LLUCH, S. *see* VILA, J.MA.
LOIRAT, C. *see* DERVIEUX, T.
LOWRY, R.C. *see* NEWBY, D.E.
LU, C. *see* LI, A.P.
LUCHT, I. *see* FREUDENTHALER, S.M.
LYNCH, P. *see* HUGHES, A.M.

MACCALLUM, H. *see* WILKINSON, I.B.
MACDONALD, I.A. *see* PEIRCE, N.S.
MACDONALD, T.M. *see* LIM, P.O.
MAGGS, J.L. *see* NAISBITT, D.J.
MAGNOLFI, G. *see* PADRINI, R.
MAGUIRE, S. *see* NUGENT, A.G.
MAISIN, A. *see* DERVIEUX, T.
MAJUMDAR, A. *see* NEWBY, D.E.
MAKOFF, A.J. *see* AITCHISON, K.J.
MALAGUARNERA, M., GIUGNO, I., RUELLO, P., RIZZO, M., MOTTA, M. & MAZZOLENI, G. Acarbose is an effective adjunct dietary therapy in the treatment of hypertriglyceridaemias, 605
MALINGRÉ, M.M., MEERUM TERWOGT, J.M., SCHELLENS, J.H.M., DUCHIN, K.L., ROSING H. & BEIJNEN, J.H. Clinical pharmacology of oral paclitaxel in a dose-escalating study, 768P
MANAP, R.A., WRIGHT, C.E., GREGORY, A., ROSTAMI-HODJEGAN, A., MELLER, S.T., KELM, G.R., LENNARD, M.S., TUCKER, G.T. & MORICE, A.H. The antitussive effect of dextromethorphan in relation to CYP2D6 activity, 382
MANGOLD, B. *see* O'GRADY, P.
MANN, R.D. *see* DUNN, N.R.
MANT, T.G.K. *see* DAWES, M.
MARING, J.G., PIERSMA, H., BONG, S.B., DEKENS, K.G., GROENEWOLD, O.G. & DE VRIES, E.G.E. Influence of liver metastases on the pharmacokinetics of 5-fluorouracil and dihydro-5-fluorouracil, 766P
MARSHALL, S. *see* THEIS, J.G.W.
MARTIN, P. *see* DANJOU, P.
MASCHER, H. *see* GROEN, H.
MASERATI, R. *see* VILLANI, P.
MATSUNO, N. *see* HORIGOME, A.
MAXWELL, S.R.J. Emergency management of acute myocardial infarction, 284
MAY, J.A. *see* BROWN, N.
MAZZOLENI, G. *see* MALAGUARNERA, M.
McAULEY, D. *see* NUGENT, A.G.
McCABE, N., ROBSON, S.C. & FORD, G.A. Nitric oxide-mediated vasodilator activity of 17β-oestradiol in forearm circulation of pre-menopausal women, 875P
McDONAGH, A.F. *see* MIZUMA, T.
McENIERY, C.M., WILKINSON, I.B., WEBB, D.J. & COCKCROFT, J.R. Proadrenomedullin N-terminal 20 peptide (PAMP) causes vasodilation in the human forearm vascular bed but is less potent than adrenomedullin, 873P
McGLEENON, B.M., DYNAN, K.B. & PASSMORE, A.P. Acetylcholinesterase inhibitors in alzheimer's disease, 471
McGREGOR, C. *see* STEWART, D.
McGURK, C. *see* NUGENT, A.G.
MÉDARD, Y. *see* DERVIEUX, T.
MEDINA, P. *see* VILA, J.MA.
MEERUM TERWOGT, J.M. *see* MALINGRÉ, M.M.
MEGSON, I. *see* WILKINSON, I.B.
MEIJER, R.P. *see* GANSEVOORT, R.T.
MEINERS, A.P. *see* ELAND, I.A.
MELLER, S.T. *see* MANAP, R.A.
MELSON, C.W. *see* MITCHELL, D.Y.
MEREDITH, P. *see* CHUNG, M.
MEUSER, T. *see* GROND, S.
MEYER, P. *see* AHLSTRÖM, H.
MICHEL, M.C. *see* NÜRNBERGER, J.
MICHEL, M.C. *see* SCHÄFERS, R.F.
MICHEL, M.C., BRESSEL, H.-U., GOEPEL, M. & RÜBBEN, H. A 6-month large-scale study into the safety of tamsulosin, 890P
MIGET, N. *see* ROSENZWEIG, P.
MIKUS, G. *see* AMMON, S.
MILLERON, B. *see* DEBRIX, I.
MITCHELL, D.Y., HEISE, M.A., PALLONE, K.A., CLAY, M.E., NESBITT, J.D., RUSSELL, D.A. & MELSON, C.W. The effect of dosing regimen on the pharmacokinetics of risedronate, 536
MIZUMA, T., McDONAGH, A.F., LIN, E.T. & BENET, L.Z. Photoinduced covalent binding of frusemide and frusemide glucuronide to human serum albumin, 79
MOERMAN, D.E. *see* DE CRAEN, A.J.M.
MORETTI, U. *see* NALDI, L.
MORICE, A.H. *see* MANAP, R.A.
MÖRIKE, K. *see* SCHWAB, M.
MOSTERD, A. *see* FEENSTRA, J.
MOTTA, M. *see* MALAGUARNERA, M.
MUCKLOW, J.C. *see* COLLIN, M.
MUECK, A.O., SEEGER, H., DEURINGER, F.U., MUECK, S. & LIPPERT, T.H. Continuous combined hormone replacement therapy in postmenopausal women: comparison of conventional oral preparation with a new combi-patch, 889P
MUECK, S. *see* MUECK, A.O.
MUIRHEAD, G.J. *see* WALKER, D.K.
MUNRO, J. *see* AITCHISON, K.J.
MURAKI, K. *see* KATO, Y.
MURRAY, R.M. *see* AITCHISON, K.J.
MUSSON, D.G. *see* VAN HAARST, A.D.

NACAK, M. *see* AYNACIOGLU, A.S.
NAGAO, T. *see* HORIGOME, A.
NAGY, J. *see* SCHIPPER, H.G.
NAGY, J., SCHIPPER, H.G., KOOPMANS, R.P., BUTTER, J.J., VAN BOXTEL, C.J. & KAGER, P.A. Grapefruit juice and a fatty meal enhance albendazole bioavailability, cimetidine co-administration decreases it, 776P
NAISBITT, D.J., MAGGS, J.L., PIRMOHAMED, M. & PARK, B.K. Metabolism of lamotrigine to a chemically reactive metabolite(s) *in vivo*: possible role in cutaneous reactions, 876P
NAKASHIMA, M. *see* UMEMURA, K.
NALDI, L., CONFORTI, A., VENEGONI, M., TRONCON, M.G., CAPUTI, A., GHIOTTO, E., COCCI, A., MORETTI, U., VELO, G. & LEONE, R. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions, 839
NEEF, C. *see* SCHUURMANS, A.
NEMANSKY, M. *see* GROEN, H.
NESBITT, J.D. *see* MITCHELL, D.Y.
NEUMAYER, H.-H., PARADIS, K., KORN, A., JEAN, C., FRITSCHE, L., BUDDE, K., WINKLER, M., KLIEM, V., PICHLMAYR, R., HAUSER, I.A., BURKHARDT, K., LISON, A.-E., BARNDT, I. & APPEL-DINGEMANSE, S. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients, 694
NEUVONEN, P.J. *see* LAPATTO-REINILUOTO, O.
NEWBY, D.E., SCIBERRAS, D.G., FERRO, C.J., GERTZ, B.J., SOMMERVILLE, D., MAJUMDAR, A., LOWRY, R.C. & WEBB, D.J. Substance P induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man, 336
NGUYEN, T. *see* SCHMUCK, S.
NICHOLAS, C. *see* WILLIAMSON, R.
NICHOLL, D.J. *see* JORGA, K.M.
NIEBCH, G. *see* DUIJKERS, I.J.M.
NIELSEN, G.L. *see* SØRENSEN, H.T.
NUGENT, A.G., McGURK, C., MCAULEY, D., MAGUIRE, S., SILKE, B. & JOHNSTON, G.D. Forearm reactive hyperaemia is not

mediated by nitric oxide in health volunteers, 457
NÜRNBERGER, J. *see* SCHÄFERS, R.F.
NÜRNBERGER, J., SIFFERT, W., PHILLIP, TH., MICHEL, M.C. & SCHÄFERS, R.F. Metabolic and haemodynamic effects of oral glucose loading in healthy men carrying the 835T-allele of the G-protein β3 subunit, 886P
NYBERG, L. *see* AHLSTRÖM, H.

O'GRADY, P., YEE, K.-F., LINS, R. & MANGOLD, B. Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics, 375
O'KANE, K.P.J. *see* SQUIRE, I.B.
O'NEIL, W.M., PEZZULLO, J.C., DI GIROLAMO, A., TSOUKAS, C.M. & WAINER, I.W. Glucuronidation and sulphation of paracetamol in HIV-positive patients and patients with AIDS, 811
OBERBAUER, R. *see* TURNHEIM, K.
OKA, K. *see* HORIGOME, A.
OLDÆUS, G. *see* AHLSTRÖM, H.
OLESEN, C. *see* SØRENSEN, H.T.
OLSEN, J. *see* SØRENSEN, H.T.
OLSSON, H. *see* AHLSTRÖM, H.
ÖNGEN, Z. *see* AYNACIOGLU, A.S.
OOSTERHOFF, E. *see* DERKS, M.G.M.
ORAVEC, S. *see* HORNYCH, A.
OUWERKERK, J. *see* KERBUSCH, T.
OXTOBY, E. *see* PHILLIPS, M.A.
ÖZKUR, M. *see* AYNACIOGLU, A.S.

PADRINI, R., PANFILI, M., MAGNOLFI, G., PIOVAN, D., CASAROTTO, D. & FERRARI, M. Myocardial region (right or left ventricle) and aetiology of heart failure can influence the inotropic effect of ouabain in failing human myocardium, 743
PAECH, M. *see* KRISTENSEN, J.H.
PAGE, M.J. *see* WALKER, D.K.
PAKUTS, A. *see* GALLICANO, K.D.
PALLARDÓ, F. *see* VILA, J.MA.
PALLONE, K.A. *see* MITCHELL, D.Y.
PANFILI, M. *see* PADRINI, R.
PARADIS, K. *see* NEUMAYER, H.-H.
PARK, B.K. *see* KITTERINGHAM, N.R.
PARK, B.K. *see* NAISBITT, D.J.
PASSMORE, A.P. *see* MCGLEENON, B.M.
PATTERSON, D.L.H. *see* VADHER, B.
PATY, I. *see* DANJOU, P.
PAULSON, S. *see* KEMME, M.J.B.
PEACOCK, I. *see* KING, P.
PEIRCE, N.S., TATTERSALL, R.B., STUBBS, T.A., MACDONALD, I.A. & ALEXANDER, S.PH. The effect of sibutramine on weight loss and glucose metabolism in obese patients with type 2 diabetes mellitus, 880P
PÉREZ-GUTTHANN, S. *see* GARCÍA RODRÍGUEZ, L.A.
PERUCCA, E. *see* XIAO DONG, S.
PETERSON, D.W. *see* CHARLETT, A.
PEZZULLO, J.C. *see* O'NEIL, W.M.
PHILIPP, TH. *see* SCHÄFERS, R.F.
PHILLIP, TH. *see* NÜRNBERGER, J.
PHILLIPS, M.A., OXTOBY, E., LANGLEY, R.W., BRADSHAW, C.M. & SZABADI, E. Effect of acute tryptophan depletion on prepulse inhibition of the acoustic startle response and auditory evoked potential in healthy volunteers, 877P
PICHLMAYR, R. *see* NEUMAYER, H.-H.
PICKKERS, P. *see* ABBINK, E.J.
PICKKERS, P. *see* DE HOON, J.N.J.M.
PIERSMA, H. *see* MARING, J.G.
PINKERTON, C.R. *see* HAIN, R.D.W.
PIOTROVSKIJ, V. *see* PREECHAGOON, Y.
PIOVAN, D. *see* PADRINI, R.
PIRMOHAMED, M. *see* NAISBITT, D.J.
PISANO, P. *see* BLIN, O.
POIRIER, J.-M. *see* RAGUENEAU, I.
POLLER, U. *see* SCHMUCK, S.
PORSIUS, A.J. *see* VAN DE VIJVER, D.A.M.C.
POTTHAST, H. *see* GLEITER, C.H.
POWELL, H. *see* KITTERINGHAM, N.R.
PREECHAGOON, Y., CHARLES, B., PIOTROVSKIJ, V., DONOVAN, T. & VAN PEER, A. Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease, 688
PROFIT, L. & BACK, D.J. The P-glycoprotein mediated transport of the HIV protease inhibitors saquinavir, ritonavir and indinavir in Caco-2 cells, 882P
PROFIT, L. *see* EAGLING, V.A.
PUENTE, J. *see* CHUNG, M.
PURDIE, D.W. & BEARDSWORTH, S.A. The selective oestrogen receptor modulation: evolution and clinical applications, 785

RADEMBINO, N. *see* RAGUENEAU, I.
RADKE, J. *see* SCHMUCK, S.
RAGUENEAU, I., POIRIER, J.-M., RADEMBINO, N., BUU SAO, A., FUNCK-BRENTANO, C. & JAILLON, P. Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers, 453
RAISTRICK, D. *see* ROSTAMI-HODJEGAN, A.
RAJMAN, I., EACHO, P.I., CHOWIENCZYK, P.J. & RITTER, J.M. LDL particle size: an important drug target?, 125
RAMSAY, L.E. *see* ROWLAND, K.
RANE, C.T. Subtherapeutic levels of phenytoin with standard doses in infants: need to review dosage schedule, 465
RANSHAW, C. *see* GREEN, J.T.
RAWLINS, M.D. *see* ELAND, I.A.
RAYMOND, K. *see* CHANG, S.
REGAZZI, M.B. *see* VILLANI, P.
REID, J.L. *see* SQUIRE, I.B.
RHODES, J. *see* GREEN, J.T.
RHODES, J. *see* HUGHES, A.M.
RITTER, J.M. *see* DAWES, M.
RITTER, J.M. *see* FISHER, I.
RITTER, J.M. *see* RAJMAN, I.
RIZZO, M. *see* MALAGUARNERA, M.
ROBB, S. *see* SQUIRE, I.B.
ROBERTS, M.S. *see* JIANG, R.
ROBINSON, P. *see* FISHER, I.
ROBSON, S.C. *see* MCCABE, N.
ROCHETTE, L. *see* LENFANT, F.
RODENHUIS, S. *see* HUITEMA, A.D.R.
RÖDER, F. *see* SCHWAB, M.
ROMEIS, P. *see* DUIJKERS, I.J.M.
RONGEN, G.A., LAMBROU, G. & SMITS, P. Flow ratios to express results obtained with the human *in vivo* 'perfused forearm technique', 258
ROOS, R.A.C. *see* VAN DE VIJVER, D.A.M.C.
ROOTS, I. *see* AYNACIOGLU, A.S.
ROOTS, I. *see* AYNACIOGLU, A.S.
ROSENBORG, J. *see* AHLSTRÖM, H.
ROSENZWEIG, P., MIGET, N. & BROHIER, S. Transaminase elevation on placebo during phase I trials: prevalence and significance, 19
ROSING, H. *see* MALINGRÉ, M.M.
ROSTAMI-HODJEGAN, A. *see* MANAP, R.A.
ROSTAMI-HODJEGAN, A. *see* TOOLEY, A.
ROSTAMI-HODJEGAN, A., WOLFF, K., HAY, A.W.M., RAISTRICK, D., CALVERT, R. & TUCKER, G.T. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes, 43
ROUMENOV, D. *see* WARY, C.
ROWE, P.H. *see* CHEN, A.G.
ROWLAND, K., YEO,, YEO, W.W., WALLIS, E.J. & RAMSAY, L.E. Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients, 610
RÜBBEN, H. *see* MICHEL, M.C.
RUDY, D.W. *see* GRUBB, N.G.
RUELLO, P. *see* MALAGUARNERA, M.

RUSSELL, D.A. *see* MITCHELL, D.Y.
RUSSELL, M.A.H. *see* GREEN, J.T.
RUTTEN, J.-P.B. *see* VAN AGTMAEL, M.A.
RÜTZ, A. *see* SCHÄFERS, R.F.

SACHSE, C. *see* AITCHISON, K.J.
SACHSE, C. *see* AYNACIOGLU, A.S.
SAHAI, J. *see* GALLICANO, K.D.
SAKURA, N. *see* KATO, Y.
SAKURAI, E. *see* HORIGOME, A.
SALES, S.D. *see* KEWN, S.
SALES, S.D., HOGGARD, P.G., HART, C.A. & BACK, D.J. Cytosolic zidovudine anabolites are responsible for cytotoxicity in isolated PBMCs, 881P
SAMSON, M.M., JANSEN, P.A.F., DE VREEDE, P., HOVESTADT, A., VAN LAAR, T. & VERHAAR, H.J.J. Quick titration of pergolide as adjunct therapy in Parkinson's disease in combination with domperidone is safe and effective in patients over the age of 65 years, 768P
SANDSTRÖM, R., KNUTSON, T.W., KNUTSON, L., JANSSON, B. & LENNERNÄS, H. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans, 180
SARIS, W.H.M. *see* SCHIFFERS, S.L.H.
SAUNDERS, D.A. *see* BEGG, E.J.
SÄWE, J. *see* BÖTTIGER, Y.
SCHAFER, I. *see* LENFANT, F.
SCHÄFERS, R.F. *see* NÜRNBERGER, J.
SCHÄFERS, R.F., NÜRNBERGER, J., RÜTZ, A., SIFFERT, W., PHILIPP, TH. & MICHEL, M.C. Vasoconstrictor response of the human dorsal hand vein in young normotensive men carrying the 825T-allele of the G-protein β3 subunit, 872P
SCHALM, S.W. *see* VULTO, A.G.
SCHELLENS, J.H.M. *see* KERBUSCH, T.
SCHELLENS, J.H.M. *see* MALINGRÉ, M.M.
SCHENCK, T. *see* FREUDENTHALER, S.M.
SCHIFFERS, S.L.H., VAN HARMELEN, V.J.A., DE GRAUW, H.A.G., SARIS, W.H.M. & VAN BAAK, M.A. Dobutamine as selective β1-adrenoceptor agonist in *in vivo* studies on human thermogenesis, 770P
SCHIPPER, H.G. *see* NAGY, J.
SCHIPPER, H.G., KOOPMANS, R.P., BUTTER, J.J., VAN BOXTEL, C.J. & KAGER, P.A. A pilot study for the feasibility of dosing albendazole guided by its albendazole sulphoxide levels, 775P
SCHIPPER, H.G., KOOPMANS, R.P., NAGY, J., BUTTER, J.J., KAGER, P.A. & VAN BOXTEL, C.J. A six-fold dose increase and cimetidine co-administration do not enhance albendazole bioavailability, 776P
SCHIPPER, H.G., KOOPMANS, R.P., NAGY, J., BUTTER, J.J., VAN BOXTEL, C.J. & KAGER, P.A. Saliva is appropriate for monitoring albendazole treatment, 783P
SCHMUCK, S., POLLER, U., JAKUBETZ, J., RADKE, J., NGUYEN, T. & BRODDE, O.-E. The intrinsic sympathomimetic activity of the β-adrenoceptor antagonist carteolol is β2-adrenoceptor mediated, 875P
SCHNEIDER, E. *see* DUIJKERS, I.J.M.
SCHNEIDER, E. *see* GLEITER, C.H.
SCHOEMAKER, R.C. *see* KEMME, M.J.B.
SCHØNHEYDER, H.C. *see* SØRENSEN, H.T.
SCHREEB, K.H. *see* GLEITER, C.H.
SCHUG, B.S. *see* GLEITER, C.H.
SCHUURMANS, A., VAN DEN BROEK, E., KOLKMAN, J.J. & NEEF, C. Some quantitative aspects of chronic acid suppressing therapy in general practice, 781P
SCHWAB, M., RÖDER, F., MÖRIKE, K., THON, K.-P. & KLOTZ, U. Drug-induced hyponatraemia in elderly patients, 105
SCHWARTZ, L. *see* DEBRIX, I.
SCIBERRAS, D.G. *see* NEWBY, D.E.
SEEGER, H. *see* MUECK, A.O.
SEGARRA, G. *see* VILA, J.MA.
SEGUIN, I. *see* GALLICANO, K.D.
SEMINARI, E. *see* VILLANI, P.
SHADER, R.I. *see* VON MOLTKE, L.L.
SHAH, J.C. *see* GUPTA, S.K.
SHAKIB, S. *see* BICKFORD, L.
SHAM, P.C. *see* AITCHISON, K.J.
SHAMSI, Z. *see* HINDMARCH, I.
SHELLEY, J.H. Phase II trials in drug development, 107
SHIH, M.-F. *see* LEWIS, D.R.
SHUKLA, V.K. *see* GALLICANO, K.D.
SIFFERT, W. *see* NÜRNBERGER, J.
SIFFERT, W. *see* SCHÄFERS, R.F.
SILKE, B. *see* NUGENT, A.G.
SINGH, S.D. & WILLIAMS, A.J. The prevalence and incidence of medical conditions in healthy pharmaceutical company employees who volunteer to participate in medical research, 25
SIRICURURAT, A. *see* AHLSTRÖM, H.
SLUITER, W.J. *see* GANSEVOORT, R.T.
SMITH, D.A. *see* WALKER, D.K.
SMITH, F.C.T. *see* LEWIS, D.R.
SMITH, S. *see* AITCHISON, K.J.
SMITS, P. *see* ABBINK, E.J.
SMITS, P. *see* BROEDERS, M.E.A.C.
SMITS, P. *see* DE HOON, J.N.J.M.
SMITS, P. *see* RONGEN, G.A.
SOMMERVILLE, D. *see* NEWBY, D.E.
SOMOGYI, A.A. *see* COLLER, J.K.
SØRENSEN, H.T., NIELSEN, G.L., OLESEN, C., LARSEN, H., STEFFENSEN, F.H., SCHØNHEYDER, H.C., OLSEN, J. & CZEIZEL, A.E. Risk of malformations and other outcomes in children exposed to fluconazole *in utero*, 234
SQUIRE, I.B., ROBB, S., BRENNAN, G., O'KANE, K.P.J., DARGIE, H.J. & REID, J.L. Blood pressure and renin angiotensis system responds to initiation of treatment with captopril or losartan in heart failure, 464
STAHLBERG, H.J. *see* GROND, S.
STANLEY, N. *see* HINDMARCH, I.
STEFFENSEN, F.H. *see* SØRENSEN, H.T.
STEIN, C.M. *see* XIE, H.G.
STEINER, J. Advances in drug delivery techniques, 467
STERRETT, A. *see* VAN HAARST, A.D.
STEWART, D., KRSKA, J., KENDLE, K., WINTOUR, D. & MCGREGOR, C. Withdrawal of peripheral vasodilators in primary care, 247
STOLK, L., DEGRAEUWE, P.L.J. & DE STOPPELAAR, F. Population pharmacokinetics of gentamicin in preterm and term neonates analyzed by the NPEM-2 algorithm, 767P
STRICKER, B.H. Achilles tendinitis associated with fluoroquinolones, 433
STRICKER, B.H.CH. *see* ELAND, I.A.
STRICKER, B.H.Ch. *see* FEENSTRA, J.
STRICKER, B.H.CH. *see* GARCÍA RODRÍGUEZ, L.A.
STRICKER, B.H.CH. *see* VAN DE VIJVER, D.A.M.C.
STRONG, J.M. *see* LI, A.P.
STRUIJKER-BOUDIER, H.A.J. *see* DE HOON, J.N.J.M.
STRUTHERS, A.D. *see* LEE, A.F.C.
STUBBS, T.A. *see* PEIRCE, N.S.
SVANSTRÖM, C. *see* BRYNNE, N.
SVENSSON, U.S.H. & ASHTON, M. Identification of the human cytochrome P450 enzymes involved in the *in vitro* metabolism of artemisinin, 528
SWEENEY, M. *see* CHUNG, M.
SZABADI, E. *see* ABDELMAWLA, A.H.
SZABADI, E. *see* BANJAR, W.M.A.
SZABADI, E. *see* PHILLIPS, M.A.

TABERNER, P.V. *see* LEWIS, D.R.
TAKAHASHI, M. *see* UMEMURA, K.
TAKEUCHI, H. *see* HORIGOME, A.
TAN, K.W. & LEENEN, F.H.H. Persistence of anti-hypertensive effect after missed dose of perindopril, 628
TATTERSALL, R.B. *see* PEIRCE, N.S.
TAVERNER, D. *see* BICKFORD, L.
THEIS, J.G.W., DEICHSEL, G. &

MARSHALL, S. Rapid development of tolerance to dipyridamole-associated headaches, 750
THOMAS, G.A.O. *see* GREEN, J.T.
THOMAS, M. *see* GLEITER, C.H.
THON, K.-P. *see* SCHWAB, M.
TIBBEN, M.M. *see* HUITEMA, A.D.R.
TIJSSEN, J.G.P. *see* DE CRAEN, A.J.M.
TOOLEY, A., ROSTAMI-HODJEGAN, A., LENNARD, M.S. & TUCKER, G.T. Acute inhibition of methadone metabolism by ritonavir: projection of interindividual variability from *in vitro* data, 883P
TORTI, C. *see* VILLANI, P.
TRONCON, M.G. *see* NALDI, L.
TSOUKAS, C.M. *see* O'NEIL, W.M.
TUCKER, G.T. *see* MANAP, R.A.
TUCKER, G.T. *see* ROSTAMI-HODJEGAN, A.
TUCKER, G.T. *see* TOOLEY, A.
TURNHEIM, K., KRIVANEK, P. & OBERBAUER, R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects, 501
TYDÉN, G *see* BÖTTIGER, Y.
TYTGAT, G.N.J. *see* DE CRAEN, A.J.M.

UEDA, K. *see* KATO, Y.
UMEMURA, K., KONDO, K., IKEDA, Y., NAKASHIMA, M., KOBAYASHI, T., TAKAHASHI, M. & YOKOYAMA, T. Pharmacokinetics and tolerability of JTE-522, a novel selective cyclooxygenase-2 inhibitor, in healthy male volunteers, 669
UNGETHÜM, W. *see* DOGTEROM, P.
UNRUH, M. *see* DANJOU, P.
URAGG, H. *see* GROND, S.

VADHER, B., PATTERSON, D.L.H. & LEANING, M. Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy, 63
VAN AGTMAEL, M.A., VAN DER WÖSTEN, T.H., RUTTEN, J.-P.B. & VAN BOXTEL, C.J. The effect of local grapefruit juice on artemether levels in Vietnamese malaria patients and healthy subjects, 773P
VAN BAAK, M.A. *see* SCHIFFERS, S.L.H.
VAN BORTEL, L.M.A.B. *see* DE HOON, J.N.J.M.
VAN BOXTEL, C.J. *see* DERKS, M.G.M.
VAN BOXTEL, C.J. *see* NAGY, J.
VAN BOXTEL, C.J. *see* SCHIPPER, H.G.
VAN BOXTEL, C.J. *see* VAN AGTMAEL, M.A.
VAN DE VIJVER, D.A.M.C., ROOS, R.A.C., PORSIUS, A.J. & DE BOER, A. Estimation of incidence of prevalence of Parkinson's disease in elderly using pharmacy records, 779P
VAN DE VIJVER, D.A.M.C., STRICKER, B.H.CH., BRETELER, M.M.B., ROOS, R.A.C. PORSIUS, A.J. & DE BOER, A. Validity of pharmacy records for identification of patients with Parkinson's disease, 779P
VAN DEN BROEK, E. *see* SCHUURMANS, A.
VAN DER WÖSTEN, T.H. *see* VAN AGTMAEL, M.A.
VAN GERVEN, J.M.A. *see* VAN HAARST, A.D.
VAN GROOTHEEST, A.C. *see* ELAND, I.A.
VAN HAARST, A.D., VAN GERVEN, J.M.A., COHEN, A.F., DE SMET, M., STERRETT, A., BIRK, K.L., FISHER, A.L., DE PUY, M.E., GOLDBERG, M.R. & MUSSON, D.G. The effects of moclobemide on the pharmacokinetics of the 5-$HT_{1B/1D}$ agonist rizatriptan in healthy volunteers, 190
VAN HARMELEN, V.J.A. *see* SCHIFFERS, S.L.H.
VAN LAAR, T. *see* SAMSON, M.M.
VAN MARLE, S.P. *see* DOGTEROM, P.
VAN MARLE, S.P. *see* GROEN, H.
VAN PEER, A. *see* PREECHAGOON, Y.
VAN ROSENDAAL, A.J. *see* ABBINK, E.J.
VAN ROSSUM, T.G.J. *see* VULTO, A.G.
VASHI, V. *see* CHUNG, M.
VELO, G. *see* NALDI, L.
VENEGONI, M. *see* NALDI, L.
VENKATAKRISHNAN, K. *see* VON MOLTKE, L.L.
VERHAAR, H.J.J. *see* SAMSON, M.M.
VIALE, P. *see* VILLANI, P.
VICHYANOND, P. *see* AHLSTRÖM, H.
VILA, J.MA., MEDINA, P., SEGARRA, G., LLUCH, P., PALLARDÓ, F., FLOR, B. & LLUCH, S. Relaxant effects of antidepressants on human isolated mesenteric arteries, 223
VILLANI, P., REGAZZI, M.B., CASTELLI, F., VIALE, P., TORTI, C., SEMINARI, E. & MASERATI, R. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients, 712
VOLKERS, C.P. *see* GROEN, H.
VOLOT, F. *see* LENFANT, F.
VON MOLTKE, L.L., GREENBLATT, D.J., GRANDA, B.W., DUAN, S.X., GRASSI, J.M., VENKATAKRISHNAN, K., HARMATZ, J.S. & SHADER, R.I. Zolpidem metabolism *in vitro*: responsible cytochromes, chemical inhibitors, and *in vivo* correlations, 89
VULINK, A.J.E. *see* GANSEVOORT, R.T.
VULTO, A.G., VAN ROSSUM, T.G.J. & SCHALM, S.W. Pharmacokinetics of intravenous glycyrrhizin after single and multiple doses in chronic hepatitis C patients, 781P

WAINER, I.W. *see* O'NEIL, W.M.
WAKELKAMP, M., BLECHERT, Å., ERIKSSON, M., GJELLAN, K. & GRAFFNER, C. The influence of frusemide formulation on diuretic effect and efficiency, 361
WALKER, D.K., HALL, K.S., MUIRHEAD, G.J., PAGE, M.J. & SMITH, D.A. Pharmacokinetics of a thromboxane synthase inhibitor, UK-141,161, in rat rabbit, dog and man, 884P
WALKER, D.K., HALL, K.S., MUIRHEAD, G.J., PAGE, M.J., SMITH, D.A. & WILD, W. Pharmacokinetics of a thromboxane receptor antagonist UK-147,535, in rat rabbit, dog and man, 885P
WALLIS, E.J. *see* ROWLAND, K.
WARY, C., BRILLAULT-SALVAT, C., BLOCH, G., LEROY-WILLIG, A., ROUMENOV, D., GROGNET, J.-M., LECLERC, J.H. & CARLIER, P.G. Effect of chronic magnesium supplementation on magnesium distribution in healthy volunteers evaluated by ^{31}P NMRS and ion selective electrodes, 655
WEBB, D.J. *see* McENIERY, C.M.
WEBB, D.J. *see* NEWBY, D.E.
WEBB, D.J. *see* WILKINSON, I.B.
WEIBULL, E. *see* AHLSTRÖM, H.
WELLER, C. *see* CHARLETT, A.
WEMER, J. *see* DOGTEROM, P.
WEMER, J. *see* GROEN, H.
WETTRELL, G. *see* AHLSTRÖM, H.
WHYTE, I.M. *see* DAWSON, A.H.
WILCOX, R.G. *see* BROWN, N.
WILD, W. *see* WALKER, D.K.
WILKINSON, G.R. *see* XIE, H.G.
WILKINSON, I.B. *see* McENIERY, C.M.
WILKINSON, I.B., MACCALLUM, H., JOHNSTON, S.M., BOYD, J.L., MEGSON, I. COCKCROFT, J.R. & WEBB, D.J. Acute oral vitamin C reduces arterial stiffness in healthy subjects, 873P
WILLEMSEN, W.N.P. *see* DUIJKERS, I.J.M.
WILLIAMS, A.J. *see* SINGH, S.D.
WILLIAMSON, R., NICHOLAS, C., YEO, K.R. & YEO, W.W. Predictions on the cost-effectiveness of four HMGCOA reductase inhibitors for primary and secondary prevention of heart disease in the UK, 879P
WILSON, A.M. & LIPWORTH, B.J. Short-term dose-response relationships

© 1999 Blackwell Science Ltd

for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults, 579
WILSON, A.M. *see* BROWN, N.
WILSON, D.A. *see* BEGG, E.J.
WING, Y.K. *see* CHEN, A.G.
WINKLER, M. *see* NEUMAYER, H.-H.
WINTOUR, D. *see* STEWART, D.
WOLF, C.R. *see* KITTERINGHAM, N.R.
WOLFF, K. *see* ROSTAMI-HODJEGAN, A.
WONG, E. *see* AHLSTRÖM, H.
WONG, S.Y. *see* CHANG, S.
WOOD, A.J.J. *see* XIE, H.G.
WORTHINGTON, P. *see* DANJOU, P.
WRIGHT, C.E. *see* MANAP, R.A.
WRIGHT, P. *see* AITCHISON, K.J.

XIAO DONG, S., ZHI PING, Z., ZHONG XIAO, W., CHONG SHU, C., FATTORE, C., GATTI, G., D'URSO, S. & PERUCCA, E. Possible enhancement of the first-pass metabolism of phenacetin by ingestion of grape juice in Chinese subjects, 638
XIE, H. *see* JIANG, J.
XIE, H.G., KIM, R.B., STEIN, C.M., WILKINSON, G.R. & WOOD, A.J.J. Genetic polymorphism of (S)-mephenytoin 4′-hydroxylation in populations of African descent, 402

YANG, C.-Q. *see* HE, G.-W.
YANG, C.-Q. *see* HE, G.-W.
YAPP, P. *see* BEGG, E.J.
YAPP, P. *see* KRISTENSEN, J.H.
YATES, R.A. *see* HUGHES, A.M.
YEE, K.-F. *see* O'GRADY, P.
YEO, K.R. *see* WILLIAMSON, R.
YEO, *see* ROWLAND, K.
YEO, W.W. *see* ROWLAND, K.
YEO, W.W. *see* WILLIAMSON, R.
YOKOYAMA, T. *see* UMEMURA, K.

ZECH, K. *see* GROEN, H.
ZEEUW, D. *see* GANSEVOORT, R.T.
ZHANG, D. *see* DERVIEUX, T.
ZHI PING, Z. *see* XIAO DONG, S.
ZHONG XIAO, W. *see* XIAO DONG, S.
ZHOU, H.H. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the *N*-demethylation of sertraline in human liver microsomes, 416
ZHU, M. *see* CHANG, S.

SUBJECT INDEX

This index was compiled from the keywords

β_2-adrenergic receptor, 761
α_1-adrenoceptors, 345
β_2-adrenoceptor, 875P
β_1-adrenoceptor agonist, 770P
α_1-adrenoceptor antagonist, 890P
β-adrenoceptor antagonist, 875P
β_2-adrenoceptor downregulation, 782P
Absorption, 180, 536
Acarbose, 605, 819
ACE inhibitors, 375, 628, 861
Achilles tendinitis, 433
Acid suppressing therapy, 781P
Acoustic rhinometry, 53
Acoustic startle response, 877P
Acquired immune deficiency syndrome, 811
Acute liver injury, 847
Acyl glucuronide, 494
Adrenal suppression, 579
Adrenomedullin, 873P
Adverse drug reaction, 230, 623, 839
Adverse events, 445, 750
Aerosol, 154
Albendazole sulphoxide, 775P
Albendazole, 775P, 776P, 783P
Albumin, 79
Aldosterone/renin ratio, 756
α-lipoic acid, 819
Allopurinol, 501
Allostery, 716
Alternative medicine, 262
Alzheimer's disease, 471
3′-amino-3′-deoxythymidine, 168
Amitriptyline, 71, 223
Angioedema, 861
Angiotensin II antagonists, 777P
Angiotensin receptor antagonists, 594
Angiotensin, 586, 594
Anterograde amnesia, 510
Antibiotic resistance, 109
Antibodies, 888P
Anticholinergic effects, 71
Anticholinesterase inhibitors, 471
Anticoagulation, 63
Antiemetics, 616
Antihistamines, 200
Antihypertensive, 643
Antimuscarinic, 553, 564
Antiplatelet activity, 57
Antitussive effect, 382
Arachidonic acid, 197
Artemether, 773P
Artemisinin, 528
Arterial stiffness, 873P
Asimadoline, 778P
Aspirin, 197, 579, 866
Asthmatic children, 299
Atorvastatin, 879P
Auditory evoked potential, 877P
Autoinduction, 669
Azothioprine, 793
Bambuterol, 299
Bayesian, 63
Beclomethasone, 866
Benign prostatic hyperplasia, 678
Bioavailability, 536, 728, 776P
Bioequivalence, 866
Bisphosphonate, 536
Black population, 395, 402
Blood ethanol, 728
Blood flow, 336
Blood pressure, 355, 464, 586
Bone markers, 579
Brain, 655
Breast cancer, 669
Budesonide, 309
Budipine, 771P
Bupivacaine, 826

C825T polymorphism, 872P
Caffeine metabolism, 663
Calcitonin gene-related peptide, 774P
Calcium channel blockers, 230
Cancer patients, 33, 770P
Candesartan, 777P
Captopril, 464
Carbomers, 485
Cardiomyopathy, 743
Cardiovascular reflexes, 889P
Carteolol, 875P
Catechol-O-methyltransferase, 513
Cerebrospinal fluid, 37
Cetirizine, 216
Charcoal, 148
Chemotherapy, 265
Children, 15, 37
Chinese, 33, 250, 886P
Chlorofluorocarbon, 866
Chlorpromazine, 323
Cholesterol reduction, 610
Chronic obstructive pulmonary disease, 772P
Chronic renal failure, 573
Cimetidine, 216, 776P
Cisapride, 688, 728
Citalopram, 148
Clinical pharmacology and therapeutics, 1
Cognitive function, 200
Cohort study, 433
Colorectal cancer, 265
Complementary medicine, 262
Compliance, 43, 628
Computer, 63
COMT inhibition, 449
Concentration-effect relationship, 801
Conjugation, 733
Contractility, 743
Controlled release, 71, 678
Coronary artery bypass grafting, 99
Coronary bypass, 207
Coronary heart disease, 879P
Coronary risk, 125
Coronary surgery, 99
Corticosteroids, 579
Cross tolerance, 99
Cutaneous reactions, 876P
Cyclophosphamide, 669, 770P
Cyclosporin A, 573, 694
CYP1A2, 158
CYP2B6, 528
CYP2C19, 158, 395, 402, 416
CYP2C8, 424
CYP2C9, 409, 416, 829
CYP2D6, 382, 388, 395, 553, 564
CYP2E1, 829
CYP3A metabolism, 180
CYP3A4, 43, 158, 528, 543, 553, 564, 610, 716, 829
Cytochrome CYP1A2, 638
Cytochrome P450 2C9, 409
Cytochrome P450 inhibition, 716
Cytochrome P450, 89, 416, 513, 528
Cytochrome P4501A2, 438, 663
Cytotoxicity, 881P

Database, 402
Decision-support, 63
Delphi technique, 616
Demethylsertraline, 416
Depression, 230, 886P
Desipramine, 345
Developing country, 649
Dextromethorphan, 382, 878P
Diabetic complications, 643
Diazepam, 148
Diclofenac, 829
Dietary supplements, 655
Digoxin, 453
Dihydro-5-fluorouracil, 766P
Dihydrocodeine, 317
Dihydromorphine, 317
Diltiazem, 610
Dipropionate, 866
Dipyridamole, 750
Disodium cromoglycate, 154
Disulfiram, 829
Dobutamine, 770P
Domperidone, 768P
Dorsal hand vein, 345, 872P
Double-blind method, 53
Downregulation, 782P
Doxazosin GITS, 678
Doxazosin, 678
Drug and therapeutic committees, 239
Drug development, 106
Drug formulation, 485
Drug interactions, 89, 134, 168, 438, 453, 553, 564, 826
Drug metabolism, 416, 553, 638

© 1999 Blackwell Science Ltd

Drug monitoring, 278
Drug selection, 239
Drug utilization review, 616
Drug–drug interactions, 733
Duodenal ulcer, 853
Duration of action, 628
Dyslipidaemia, 874P

Eczema, 262
EEG, 323
Efavirenz, 712
Effect compartment, 801
Efficiency, 361
Elderly, 105, 501, 779P, 869
Emergency management, 284
Enantiomers, 250, 494, 772P, 819
Endothelium, 223, 336
Enemas, 481
Enteric-coated aspirin, 57
Enzyme induction model, 669
Enzyme induction, 43
Eosinophils, 579
Epidemiology, 847
Episodic memory, 510
Erythrocytes, 655, 826
Erythromycin, 829
Erythropoietin, 631
Essential hypertension, 460
Ethinyloestradiol, 722
Ethnicity, 861
Europe, 15
Extended release, 361

Fantofarone, 801
Fenoterol, 631
Fexofenadine, 200
First-pass metabolism, 728
Flow ratios, 258
Fluconazole, 234
Flumazenil, 826
Fluoroquinolones, 433
5-fluorouracil, 766P
Fluoxetine, 521
Fluticasone propionate, 579
Fluvastatin, 879P
Food, 536
Forearm blood flow, 258, 457
Forearm resistance vasculature, 460
Forearm vascular bed, 873P
Formoterol, 772P
Fosinopril, 375
Fosinoprilat, 375
Frusemide glucuronide, 79
Frusemide, 79, 355, 361
Futile cycle, 494

Gastric lavage, 148
Gastrointestinal therapeutic system, 678
Gender, 874P
General practice research database, 847
General practice, 781P
Genetic polymorphism, 382, 402
Genotype, 158, 388, 395
Gentamicin, 767P
Glibenclamide, 780P, 819
Glimepiride, 780P
Glucose loading, 886P
Glucose metabolism, 880P
Glucose, 819
Glucuronidation, 513, 733
Glycaemic control, 643
Glycoprotein receptors, 197
Glycyrrhizin, 781P
G-protein β3 subunit, 872P, 886P
GR32191B, 207
Grape juice, 638
Grapefruit juice, 543, 773P, 776P, 829

H_1-receptors, 216
H_2-receptors, 216
Haemodialysis, 494
Haemodynamics, 336, 801
Headaches, 750
Healthy volunteers, 19, 190, 453, 631, 801, 819
Healthy, 25
Heart failure, 464
Helicobacter pylori, 888P
Hepatitis B virus, 883P
Hepatitis C, 781P
Hepatocytes, 733
Hepatotoxicity, 887P
High ambient temperature, 889P
Histamine, 216
HIV infection, 704, 811
HIV protease inhibitors, 880P, 882P
HIV-1 infection, 712
HMGCoA reductase inhibitors, 879P
Hormone replacement therapy, 889P
$5\text{-}HT_{1B/1D}$ agonist, 190
Human artery, 207
Human liver microsomes, 158, 416, 424
Human mesenteric artery, 223
Human milk, 521
Human myocardium, 743
Human peripheral blood mononuclear cells, 573
Human, 142, 733
Hydrochlorothiazide, 375
Hydrofluoroalkane, 886
4-hydroxycyclophosphamide, 669
5-hydroxytryptamine, 331
Hypertension, 628, 678, 756
Hypertriglyceridaemia, 605
Hypnotic, 367
Hypoglycaemia, 134
Hypolipaemic drugs, 605
Hyponatraemia, 105

Ibuprofen, 148
Ifosfamide, 780P
Imipramine, 886P
Immunosuppressant, 694
Impact of guidelines, 616
In utero exposure, 521
In vitro metabolism, 89
In vitro probes, 716
Incidence, 25
Indinavir, 880P, 882P
Induction, 168, 733

Infant dose, 142, 521
Infants, 688
Information resources, 239
Inhibitors, 594
Initiation, 63
Insulin, 819
Interaction, 190, 610, 819
Internal mammary artery, 207
Intestinal permability, 180
Intestinal secretion, 180
Intrinsic sympathomimetic activity, 875P
Ion-selective electrode, 655
Iontophoresis, 216
Irbesartan, 777P
Ischaemic heart disease, 284
Isotonic saline, 154
Itraconazole, 829

Ketamine, 878P
Ketoconazole, 89, 180, 564
Ketoprofen, 494

Lamivudine, 250, 883P
Lamotrigine, 876P
Laser-Doppler fluximetry, 216
LDL subfractions, 125
Left ventricle, 743
Levodopa/carbidopa, 449
Licensed indications, 5
Licensing legislation, 5
Licensing, 15
γ-linoleic acid, 869
Lipoprotein lipase activity, 874P
Liver blood flow, 769P
Liver metastases, 766P
Local cooling, 216
Loratadine, 200
Lorazepam, 510
Losartan, 464, 631, 777P
Low-dose aspirin, 57
Lymphocyte sensitivity, 573

Macrogol 4000, 453
Magnesium, 655
Malaria, 773P
Malformations, 234
MAO-A inhibitor, 190
Medical conditions, 25
(S)-mephenytoin, 158
(S)-mephenytoin hydroxylation, 402
Meta-analysis, 402
Metabolic probe, 663
Metabolism, 388, 528, 733
Methadone, 43, 883p
Methylation, 513
3-*O*-methyltolcapone, 513
Microencapsulated aspirin, 57
Milk, 142
Moclobemide, 190
Molecular epidemiology, 761
Monoclonal antibody, 416
Morphine, 37
Morphine-6-glucuronide, 37
Multiple dose, 317
Myocardial infarction, 284

Nasal airways, 53
Nebivolol, 460
Nelfinavir, 712
Neonates, 767P
Netilmicin, 33
Neurokinin 1 receptor, 336
New agents, 265
N^G-monomethyl-L-arginine, 460
Nicotine, 481, 485
Nitric oxide, 355, 457, 460, 875P
Nitroglycerin, 99
NMDA receptors, 878P
Non-linear mixed effect model, 594
NONMEM, 688, 780P
Non-steroidal anti-inflammatory drugs, 766P
Norfluoxetine, 521
Nortriptyline, 223
NPEM-2 algorithm, 767P
Nuclear magnetic resonance, 655

Obese patients, 880P
Observational studies, 847
17β-oestradiol, 875P
Oestrogen receptor modulation, 785
Off-label medicines, 15
Omeprazole, 416
Opioid, 254
κ-opioid receptor agonist, 778P
Oral antifungals, 847
Oral hypoglycaemic agents, 643
Osteoporosis, 536, 785
Ouabain, 743
Overdose, 278
Oxidative metabolism, 513
Oxidative stress, 826
Oxipurinol, 501
Oxymetazoline, 53

Paclitaxel, 768P
Paediatric prescribing, 5
Paediatric, 793
Paget's disease, 536
Paracetamol, 638, 811, 887P
Parkinson's disease, 449, 768P, 779P, 888P
Paroxetine, 142, 345
Pergolide, 768P
Peripheral vasodilators, 247
P-glycoprotein, 180, 543, 882P
Pharmacodynamics, 71, 361, 375, 453, 501, 594, 678
Pharmacoepidemiology, 433
Pharmacogenetics, 409, 416
Pharmacokinetic interaction, 712
Pharmacokinetic-pharmacodynamic analysis, 510
Pharmacokinetics, 33, 168, 190, 250, 254, 299, 309, 317, 375, 388, 449, 453, 501, 536, 678, 694, 699, 71, 766P, 769P, 771P, 778P, 780P, 781P, 884P, 885P, 886
Pharmacometrics, 586
Pharmacy records, 779P
Phase I, 19
Phase II trials, 106
Phenacetin, 638
Phenylephrine, 355
Phenytoin, 409
Photoallergy, 79
Photoplethysmography, 586
Phototoxicity, 79
PK-PD modelling, 801
Placebo effect, 853
Placebo, 19
Plasma concentration, 154
Plasma potassium, 772P
Plasma, 37, 655
Platelets, 197
PNU-200577, 553
Poisoned patient, 278
Polymorphism, 761
Population kinetics, 43
Population pharmacokinetics, 688, 767P
Post-menopausal women, 889P
Postoperative pain, 254
Potassium channels, 774P
Pravastatin, 879P
Prednisolone, 573, 579
Pregnancy, 234
Pre-menopausal women, 875P
Prepulse inhibition, 877P
Prevalence, 25
Primary aldosteronism, 756
Primary care, 247
Proadrenomedullin N-terminal 20 peptide, 873P
Procaterol solution, 154
Proguanil, 158
Promethazine, 200
Prostaglandins, 869
Proton pump inhibitors, 438
Psychomotor function, 323
Psychomotor performance, 200
Pulmonary function, 772P

Quinidine, 829

Radial artery, 99, 207
Randomized clinical trial, 53
Rational pharmacotherapy, 239
Reactive hyperaemia, 457
Reactive metabolite, 876P
Recombinant tissue factor pathway inhibitor, 769P
Reflux disease, 688
Renal impairment, 134
Renal insufficiency, 375
Renal transplantation, 445, 573, 793
Renin, 355
Renin angiotensin system, 464, 631
Residual effects, 367
Reversed-phase high-performance liquid chromatography, 154
Rhinomanometry, 53
Rifabutin, 704
Rifampicin, 168
Right ventricle, 743
Risedronate, 536
Risperidone, 323
Ritonavir, 880P, 882P, 883P
Rizatriptan, 190
Rosiglitazone, 424

Safety, 234, 694, 890
Saliva, 783P
Saquinavir, 880P, 882P
Screening, 25
SDZ RAD, 694
Sedative, 367
Selection criteria, 239
Selective serotonin reuptake inhibitors, 105, 416
Sertraline, 223, 416
Sibutramine, 880P
Sigmoid model, 801
Simvastatin, 610, 879P
Single dose, 317
Skeletal muscle, 655
Skin penetration, 635
Skin, 839
Smooth muscle, 223
Sodium nitroprusside, 99
Soft tissue sarcoma, 780P
Spironolactone, 756
Spontaneous reporting, 138, 623, 839
Stroke prevention, 750
Substance P, 336
Sulphaphenazole, 416
Sulphation, 733
Sumatriptan, 331
Sunscreen, 635
Survey, 15
Systemic review, 262
Systolic cardiac function, 766P
Systolic time intervals, 331

Tacrine metabolism, 663
Tacrolimus, 445, 573
835T-allele, 886P
Tamsulosin, 890P
Target concentration intervention, 9
Tendinitis, 433
Terbutaline, 299
The Netherlands, 239
Theophylline, 438, 782P
Therapeutic drug monitoring, 9, 649
Thermogenesis, 770P
Thioctic acid, 819
Thiopurine methyltransferase, 793
Thiotepa, 770P
Thromboxane A_2, 207
Thromboxane antagonists, 207
Thromboxane receptor antagonist, 885P
Thromboxane synthase inhibitor, 884P
Tirofiban, 197
Tolcapone, 449, 513
Tolerance, 99
Tolterodine, 553, 564
Topical application, 635
Toxicity, 278
Traditional Chinese medicine, 262
Tramadol, 254

© 1999 Blackwell Science Ltd

Transaminases, 19
Transdermal patches, 481
Transplantation, 694
Treatment-refractory, 388
Tryptophan, 877P
Turbuhaler®, 309
Turkey, 409
Turkish population, 761
Type II diabetes, 134, 643, 780P, 880P
Typical antipsychotics, 388

UK-141,161, 884P
UK-147,535, 885P
UKPDS, 643
Ulcerative colitis, 481, 485
Ultrasonic nebulizer, 154
Unlicensed drugs, 5
Uric acid, 501
Urinary incontinence, 553, 564

Valsartan, 777P
Variability, 663
Vasoconstriction, 99, 331
Vasodilatation, 873P, 875P
Vein graft re-stenosis, 874P
Venlafaxine, 345
Verapamil, 180, 772P
Vietnamese, 773P
Vitamin C, 873P
Volunteer, 25

Warfarin, 63
Wasting syndrome, 704
Whole blood concentration, 445
'Wind up' model, 878P

Yellow card system, 138

Zaleplon, 367
Zidovudine, 881P
Zolpidem, 89, 367